<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53732">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02016131</url>
  </required_header>
  <id_info>
    <org_study_id>CQDSA_EVAR</org_study_id>
    <nct_id>NCT02016131</nct_id>
  </id_info>
  <brief_title>CQDSA for Evaluation of Endoleak in EVAR</brief_title>
  <official_title>Risk Assessment of Type I Endoleaks During Endovascular Aortic Repair by Color-coded Quantitative Digital Subtraction Angiography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Siemens Ltd., China, Shanghai, China.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Re-hospitalization or re-intervention is sometimes necessary to treat type I endoleaks after
      EVAR. Color-coded quantitative digital subtraction angiography (CQDSA) provides an easy and
      quick way to post-process the traditional digital subtraction angiography (DSA) which
      converts the peak time of the maximal contrast medium intensity into a single polychromatic
      image. With the help of CQDSA, a quantitative evaluation of the endoleak hemodynamics and a
      risk analysis of the type I endoleak could be performed during the EVAR procedure. This
      approach may offer an objective assessment of the needs for immediate re-intervention,
      conservative therapy or treatment endpoint in the future.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intra-procedural DSA series are transferred to a research workstation to generate the
      color-coded images and make quantitative measurements. Region of interest (ROI) measurements
      are performed equivalently in the endoleak and the aorta after the image generation. A small
      circle ROI is selected in the vicinity of the endoleak entry which reflected the endoleak
      hemodynamics of the endoleak to the utmost extent, and a reference at the same latitude
      within the aorta.

      The following parameters will be acquired through the CQDSA for analysis.

        1. Time-versus-ROI contrast intensity graph. The graph contains one endoleak ROI flow
           curve and one reference aortic flow curve (Ref). The x-axis shows time from 0 second to
           the maximum frame time of the image. The y-axis shows the sum of pixel intensities,
           namely total contrast, representing the contrast concentration within the ROI.

        2. ROI Peak/Ref Peak. It is the ratio of intensity peak between the endoleak and the
           reference in the aorta.

        3. ROI TTP (Time to peak). Peak time of ROI in the vicinity of endoleak entry.

        4. ROI AUC/Ref AUC. Area under curve (AUC) is calculated through Time-versus-ROI contrast
           intensity graph. The parameter here is the ratio of ROI AUC in endoleak to the
           reference.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Time-versus-ROI contrast intensity graph.</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>The graph contains one endoleak ROI flow curve and one reference aortic flow curve (Ref). The x-axis shows time from 0 second to the maximum frame time of the image. The y-axis shows the sum of pixel intensities, namely total contrast, representing the contrast concentration within the ROI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ROI Peak/Ref Peak</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>It is the ratio of intensity peak between the endoleak and the reference in the aorta.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ROI TTP (Time to peak)</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Peak time of ROI in the vicinity of endoleak entry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ROI AUC/Ref AUC</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under curve (AUC) is calculated through Time-versus-ROI contrast intensity graph. The parameter here is the ratio of ROI AUC in endoleak to the reference.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Endoleak</condition>
  <condition>Aortic Aneurysm, Abdominal</condition>
  <arm_group>
    <arm_group_label>non-persistent endeleak</arm_group_label>
    <description>Patients who undergo decrease or disappearance of endoleaks or decrease of aneurysm sac</description>
  </arm_group>
  <arm_group>
    <arm_group_label>persistent endoleak</arm_group_label>
    <description>Patients who undergo persistent or increasing endoleaks in the aneurysms or enlargement of aneurysms or rupture during follow up.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who present type I endoleak after EVAR for AAA.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who present type I endoleak after EVAR for AAA and complete at least 6
             months' follow up.

        Exclusion Criteria:

          -  Patients who present other type endoleak after EVAR for AAA. Patients who die from
             non aneurysm-reltated reasons or are lost during follow up.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weiguo Fu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai Zhongshan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhenyu Shi, MD</last_name>
    <email>maxshizhenyu@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zijie Su, MD</last_name>
    <email>HenrySu1220@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinpei Huang</last_name>
      <email>huang.jinpei@zs-hospital.sh.cn</email>
    </contact>
    <investigator>
      <last_name>Zhenyu Shi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zijie Su, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Weiguo Fu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daqiao Guo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xin Xu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bin Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Junhao Jiang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jue Yang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ting Zhu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhihui Dong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yuqi Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Janina Beilner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kaiyi Huang, Dipl.-Ing</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 14, 2013</lastchanged_date>
  <firstreceived_date>December 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Zhenyu Shi</investigator_full_name>
    <investigator_title>Associate Prof.</investigator_title>
  </responsible_party>
  <keyword>endoleak</keyword>
  <keyword>EVAR</keyword>
  <keyword>AAA</keyword>
  <keyword>CQDSA</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
    <mesh_term>Endoleak</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
